Keryx Biopharmaceuticals Inc. (KERX): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Keryx Biopharmaceuticals ( KERX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Keryx Biopharmaceuticals rose $0.29 (3.6%) to $8.32 on average volume. Throughout the day, 6,261,648 shares of Keryx Biopharmaceuticals exchanged hands as compared to its average daily volume of 8,220,700 shares. The stock ranged in a price between $8.06-$8.64 after having opened the day at $8.06 as compared to the previous trading day's close of $8.03. Other companies within the Health Care sector that increased today were: ARCA biopharma ( ABIO), up 47.2%, Tranzyme ( TZYM), up 25.7%, Catalyst Pharmaceutical Partners ( CPRX), up 20.2% and MediciNova ( MNOV), up 12.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. Keryx Biopharmaceuticals has a market cap of $621.6 million and is part of the drugs industry. Shares are up 190.5% year to date as of the close of trading on Friday.

TheStreet Ratings rates Keryx Biopharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.

On the negative front, Oxygen Biotherapeutics ( OXBT), down 8.4%, Biostar Pharmaceuticals ( BSPM), down 8.3%, SunLink Health Systems ( SSY), down 7.9% and Anacor Pharmaceuticals ( ANAC), down 7.9% , were all laggards within the health care sector with Valeant Pharmaceuticals International ( VRX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar